Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru

This study was made possible through the financial support of the Instituto Nacional de Salud (National Institute of Health, Lima, Peru) and the PROVAC Initiative of the Pan American Health Organization (Washington, DC, USA). This study was presented at 9th International Symposium of Pneumococci and...

Descripción completa

Detalles Bibliográficos
Autores: Mezones-Holguin E., Canelo-Aybar C., Clark A.D., Janusz C.B., Jaúregui B., Escobedo-Palza S., Hernandez A.V., Vega-Porras D., González M., Fiestas F., Toledo W., Michel F., Suárez V.J.
Tipo de recurso: artículo
Fecha de publicación:2015
País:Perú
Institución:Consejo Nacional de Ciencia Tecnología e Innovación
Repositorio:CONCYTEC-Institucional
Idioma:inglés
OAI Identifier:oai:repositorio.concytec.gob.pe:20.500.12390/655
Acceso en línea:https://hdl.handle.net/20.500.12390/655
https://doi.org/10.1016/j.vaccine.2014.12.039
Access Level:acceso abierto
Palabra clave:Pneumococcus vaccine
10-valent pneumococcal conjugate vaccine
13-valent pneumococcal vaccine
acute otitis media
Descripción
Sumario:This study was made possible through the financial support of the Instituto Nacional de Salud (National Institute of Health, Lima, Peru) and the PROVAC Initiative of the Pan American Health Organization (Washington, DC, USA). This study was presented at 9th International Symposium of Pneumococci and Pneumococcal Diseases, Hyderabad, India, March 2014, and supported by the National Council of Science, Technology and Technological Innovation of Peru (CONCYTEC) and International Clinical Epidemiology Network (INCLEN Trust).

Similares en LA Referencia